{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:49:00Z","timestamp":1760708940827},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T00:00:00Z","timestamp":1446508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s13277-015-4317-y","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T23:43:33Z","timestamp":1446507813000},"page":"4901-4907","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hotspot TERT promoter mutations are rare events in testicular germ cell tumors"],"prefix":"10.1007","volume":"37","author":[{"given":"Flavio Mavignier","family":"C\u00e1rcano","sequence":"first","affiliation":[]},{"given":"Daniel Onofre","family":"Vidal","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9","family":"van Helvoort Lengert","sequence":"additional","affiliation":[]},{"given":"Cristovam Scapulatempo","family":"Neto","sequence":"additional","affiliation":[]},{"given":"Luisa","family":"Queiroz","sequence":"additional","affiliation":[]},{"given":"Herlander","family":"Marques","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"Baltazar","sequence":"additional","affiliation":[]},{"given":"Camila Maria","family":"da Silva Martinelli","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[]},{"given":"Eduardo Caetano Albino","family":"da Silva","sequence":"additional","affiliation":[]},{"given":"Luiz Fernando","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,11,3]]},"reference":[{"issue":"5","key":"4317_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. doi: 10.1016\/j.cell.2011.02.013 .","journal-title":"Cell"},{"issue":"6122","key":"4317_CR2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957\u20139. doi: 10.1126\/science.1229259 .","journal-title":"Science"},{"key":"4317_CR3","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","volume":"4","author":"J Vinagre","year":"2013","unstructured":"Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185. doi: 10.1038\/ncomms3185 .","journal-title":"Nat Commun"},{"issue":"15","key":"4317_CR4","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","volume":"110","author":"PJ Killela","year":"2013","unstructured":"Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021\u20136. doi: 10.1073\/pnas.1303607110 .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6122","key":"4317_CR5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","volume":"339","author":"S Horn","year":"2013","unstructured":"Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959\u201361. doi: 10.1126\/science.1230062 .","journal-title":"Science"},{"issue":"6238","key":"4317_CR6","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.aab0015","volume":"348","author":"RJ Bell","year":"2015","unstructured":"Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015;348(6238):1036\u20139. doi: 10.1126\/science.aab0015 .","journal-title":"Science"},{"issue":"10","key":"4317_CR7","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.18632\/oncotarget.1975","volume":"5","author":"CK Park","year":"2014","unstructured":"Park CK, Lee SH, Kim JY, Kim JE, Kim TM, Lee ST, et al. Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget. 2014;5(10):3399\u2013407.","journal-title":"Oncotarget"},{"issue":"43","key":"4317_CR8","doi-asserted-by":"crossref","first-page":"17426","DOI":"10.1073\/pnas.1310522110","volume":"110","author":"PS Rachakonda","year":"2013","unstructured":"Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013;110(43):17426\u201331. doi: 10.1073\/pnas.1310522110 .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4317_CR9","author":"I Hosen","year":"2014","unstructured":"Hosen I, Rachakonda PS, Heidenreich B, Sitaram RT, Ljungberg B, Roos G, et al. TERT promoter mutations in clear cell renal cell carcinoma. Int J Cancer. 2014. doi: 10.1002\/ijc.29279 .","journal-title":"Int J Cancer"},{"issue":"10","key":"4317_CR10","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/ncpuro0606","volume":"3","author":"F Bray","year":"2006","unstructured":"Bray F, Ferlay J, Devesa SS, McGlynn KA, Moller H. Interpreting the international trends in testicular seminoma and nonseminoma incidence. Nat Clin Pract Urol. 2006;3(10):532\u201343. doi: 10.1038\/ncpuro0606 .","journal-title":"Nat Clin Pract Urol"},{"issue":"11","key":"4317_CR11","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1990.8.11.1777","volume":"8","author":"LH Einhorn","year":"1990","unstructured":"Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol: Off J Am Soc Clin Oncol. 1990;8(11):1777\u201381.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"33","key":"4317_CR12","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","volume":"28","author":"A Lorch","year":"2010","unstructured":"Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(33):4906\u201311. doi: 10.1200\/JCO.2009.26.8128 .","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"2","key":"4317_CR13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.bjc.6602682","volume":"93","author":"GM Mead","year":"2005","unstructured":"Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJ, Cook PA, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer. 2005;93(2):178\u201384. doi: 10.1038\/sj.bjc.6602682 .","journal-title":"Br J Cancer"},{"issue":"15","key":"4317_CR14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/jnci\/91.15.1321","volume":"91","author":"J Albanell","year":"1999","unstructured":"Albanell J, Bosl GJ, Reuter VE, Engelhardt M, Franco S, Moore MA, et al. Telomerase activity in germ cell cancers and mature teratomas. J Natl Cancer Inst. 1999;91(15):1321\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"4317_CR15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ng.607","volume":"42","author":"C Turnbull","year":"2010","unstructured":"Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet. 2010;42(7):604\u20137. doi: 10.1038\/ng.607 .","journal-title":"Nat Genet"},{"issue":"2","key":"4317_CR16","first-page":"103","volume":"22","author":"WG Dirks","year":"2005","unstructured":"Dirks WG, Faehnrich S, Estella IA, Drexler HG. Short tandem repeat DNA typing provides an international reference standard for authentication of human cell lines. ALTEX. 2005;22(2):103\u20139.","journal-title":"ALTEX"},{"issue":"6","key":"4317_CR17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bjc.6605225","volume":"101","author":"O Martinho","year":"2009","unstructured":"Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, Silva A, et al. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer. 2009;101(6):973\u201382. doi: 10.1038\/sj.bjc.6605225 .","journal-title":"Br J Cancer"},{"key":"4317_CR18","author":"NC Campanella","year":"2014","unstructured":"Campanella NC, Celestino R, Pestana A, Scapulatempo-Neto C, de Oliveira AT, Brito MJ, et al. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). Eur J Hum Genet: EJHG. 2014. doi: 10.1038\/ejhg.2014.195 .","journal-title":"Eur J Hum Genet: EJHG"},{"key":"4317_CR19","author":"NC Campanella","year":"2015","unstructured":"Campanella NC, Penna V, Abrahao-Machado LF, Cruvinel-Carloni A, Ribeiro G, Soares P, et al. TERT promoter mutations in soft tissue sarcomas. Int J Biol Markers. 2015. doi: 10.5301\/jbm.5000168 .","journal-title":"Int J Biol Markers"},{"issue":"2","key":"4317_CR20","first-page":"594","volume":"15","author":"IGCCCG","year":"1997","unstructured":"IGCCCG. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. Int Germ Cell Cancer Collab Group J Clin Oncol: Off J Am Soc Clin Oncol. 1997;15(2):594\u2013603.","journal-title":"Int Germ Cell Cancer Collab Group J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"4317_CR21","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ncomms3218","volume":"4","author":"JC Nault","year":"2013","unstructured":"Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218. doi: 10.1038\/ncomms3218 .","journal-title":"Nat Commun"},{"key":"4317_CR22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.gde.2013.11.005","volume":"24c","author":"B Heidenreich","year":"2014","unstructured":"Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014;24c:30\u20137. doi: 10.1016\/j.gde.2013.11.005 .","journal-title":"Curr Opin Genet Dev"},{"issue":"5","key":"4317_CR23","doi-asserted-by":"crossref","first-page":"E754","DOI":"10.1210\/jc.2013-3734","volume":"99","author":"M Melo","year":"2014","unstructured":"Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754\u201365. doi: 10.1210\/jc.2013-3734 .","journal-title":"J Clin Endocrinol Metab"},{"key":"4317_CR24","author":"H Populo","year":"2014","unstructured":"Populo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, et al. TERT promoter mutations in skin cancer: the effects of sun exposure and x-irradiation. J Invest Dermatol. 2014. doi: 10.1038\/jid.2014.163 .","journal-title":"J Invest Dermatol"},{"issue":"13","key":"4317_CR25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2008.18.8623","volume":"27","author":"F Honecker","year":"2009","unstructured":"Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(13):2129\u201336. doi: 10.1200\/JCO.2008.18.8623 .","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"2","key":"4317_CR26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ijc.20567","volume":"113","author":"F Sommerer","year":"2005","unstructured":"Sommerer F, Hengge UR, Markwarth A, Vomschloss S, Stolzenburg JU, Wittekind C, et al. Mutations of BRAF and RAS are rare events in germ cell tumours. Int J Cancer. 2005;113(2):329\u201335. doi: 10.1002\/ijc.20567 .","journal-title":"Int J Cancer"},{"issue":"2","key":"4317_CR27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00428-014-1608-4","volume":"465","author":"J Vinagre","year":"2014","unstructured":"Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P, et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch: Int J Pathol. 2014;465(2):119\u201333. doi: 10.1007\/s00428-014-1608-4 .","journal-title":"Virchows Arch: Int J Pathol"},{"issue":"7422","key":"4317_CR28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature11632","volume":"491","author":"GR Abecasis","year":"2012","unstructured":"Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56\u201365. doi: 10.1038\/nature11632 .","journal-title":"Nature"},{"issue":"Pt 8","key":"4317_CR29","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1242\/jcs.115.8.1643","volume":"115","author":"S Dolci","year":"2002","unstructured":"Dolci S, Levati L, Pellegrini M, Faraoni I, Graziani G, Di Carlo A, et al. Stem cell factor activates telomerase in mouse mitotic spermatogonia and in primordial germ cells. J Cell Sci. 2002;115(Pt 8):1643\u20139.","journal-title":"J Cell Sci"},{"issue":"5","key":"4317_CR30","first-page":"1097","volume":"9","author":"M Schrader","year":"2002","unstructured":"Schrader M, Burger AM, Muller M, Krause H, Straub B, Smith GL, et al. Quantification of human telomerase reverse transcriptase mRNA in testicular germ cell tumors by quantitative fluorescence real-time RT-PCR. Oncol Rep. 2002;9(5):1097\u2013105.","journal-title":"Oncol Rep"},{"issue":"35","key":"4317_CR31","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1038\/sj.onc.1203746","volume":"19","author":"R Nowak","year":"2000","unstructured":"Nowak R, Sikora K, Pietas A, Skoneczna I, Chrapusta SJ. Germ cell-like telomeric length homeostasis in nonseminomatous testicular germ cell tumors. Oncogene. 2000;19(35):4075\u20138. doi: 10.1038\/sj.onc.1203746 .","journal-title":"Oncogene"},{"issue":"5","key":"4317_CR32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrg2763","volume":"11","author":"AJ Cesare","year":"2010","unstructured":"Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet. 2010;11(5):319\u201330. doi: 10.1038\/nrg2763 .","journal-title":"Nat Rev Genet"},{"key":"4317_CR33","unstructured":"Ries LAG YJ, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988\u20132001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07\u20136215, Bethesda, MD, 2007; p165-70. 2007."},{"issue":"8","key":"4317_CR34","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1200\/JCO.2008.16.4202","volume":"27","author":"LF Lopes","year":"2009","unstructured":"Lopes LF, Macedo CR, Pontes EM, Dos Santos AS, Mastellaro MJ, Melaragno R, et al. Cisplatin and etoposide in childhood germ cell tumor: Brazilian pediatric oncology society protocol GCT-91. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(8):1297\u2013303. doi: 10.1200\/JCO.2008.16.4202 .","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4317-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-4317-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4317-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T01:26:57Z","timestamp":1653442017000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-4317-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,3]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["4317"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-4317-y","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,3]]}}}